FDA and NIH could both face significant funding cuts if the executive branch is unable to reach an agreement with Congress on required spending cuts.
At issue for FDA is the baseline taxpayer funding that must be in place before the agency can use money from user fees, which are collected from drug, device and tobacco companies to support the work of the agency. The loss of those funds has the potential to bring reviews of new drugs and devices to a standstill in January 2013.
NIH stands to lose as much as US $2.4B, which could lead to the cancellation of numerous research grants.
